Literature DB >> 838846

Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man.

J W Benson, D G Johnson, J P Palmer, P L Werner, J W Ensinck.   

Abstract

To examine the role of catecholamines in glucopenia-induced glucagon secretion, urinary epinephrine and norepinephrine and plasma immunoreactive glucagon (IRG) were measured during insulin-induced hypoglycemia in normal and insulin-dependent diabetic-man. Despite equivalent levels of hypoglycemia the mean plasma IRG increment in diabetes was only 15% of normals. The increases in epinephrine and norepinephrine were comparable in diabetics and normals; thus, the blunted response in plasma IRG to the stimulus of low blood sugar in diabetics cannot be explained by a generalized defect in catecholamine secretion. It is suggested that an alpha-cell glucoreceptor defect may account for the abnormal response to glucopenia in diabetics. To evaluate the possibility that impaired sensitivity to circulating catecholamines could explain the alpha cell dysfunction in diabetics, exogenous epinephrine was infused in normals and insulin-dependent diabetics. Elevated plasma IRG during epinephrine infusion was observed in only 50% of normals. The diabetics were hyperresponsive; mean increment in plasma IRG 3 times that of normals. The data demonstrate enhanced rather than impaired sensitivity to catecholamines in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 838846     DOI: 10.1210/jcem-44-3-459

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Actions of salbutamol in late pregnancy: plasma cyclic AMP, insulin and C-peptide, carbohydrate and lipid metabolites in diabetic and non-diabetic women.

Authors:  B B Fredholm; N O Lunell; B Persson; J Wager
Journal:  Diabetologia       Date:  1978-04       Impact factor: 10.122

2.  Transient insulin resistance following infusion of adrenaline in type 1 (insulin-dependent) diabetes mellitus.

Authors:  M Kollind; U Adamson; P E Lins; B Hamberger
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 3.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

Review 4.  Catecholamines and diabetes mellitus.

Authors:  N J Christensen
Journal:  Diabetologia       Date:  1979-04       Impact factor: 10.122

5.  Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Acta Diabetol Lat       Date:  1985 Apr-Jun

Review 6.  Insulin-counteracting hormones: their impact on glucose metabolism.

Authors:  P R Bratusch-Marrain
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

7.  Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.

Authors:  M A Berk; W E Clutter; D Skor; S D Shah; R P Gingerich; C A Parvin; P E Cryer
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.

Authors:  D A Popp; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes.

Authors:  I Lager; H von Schenck; U Smith
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

Review 10.  Early sympathetic islet neuropathy in autoimmune diabetes: lessons learned and opportunities for investigation.

Authors:  Thomas O Mundinger; Gerald J Taborsky
Journal:  Diabetologia       Date:  2016-06-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.